Prana Biotechnology (PRAN)

[frobinso]

Keep in mind that the Reach2HD trial for Huntingtons also using PBT2 involves five Australia locations and 15 U.S. locations and is only a six month trial now with their first patient past the 3 month mark. There will likely be a trial update on this trial later this month, or early November...

PBT434 is a Prana pipeline drug tailored to Parkinsons that recently met it's milestones in the Michael J. Fox Foundation's drug development program, and is funded by that program.

PBT519 for Brain cancer I have not heard much about for some time.

They have an 800+ MPAC library, that was, very nicely, independently supported by Susan Lindquist's published findings - thought to be an approach that may work across a broad range of nuerodegeneratvie conditions...

http://www.marketwire.com/press-release/landmark-publication-endorses-pranas-drug-pipeline-strategy-treating-neurodegenerative-nasdaq-pran-1599565.htm

Prana recently held a webcast to clarify that the recent failures of BAPI/SOLA in no way indicate a negative outcome for Prana's PBT2, but quite the contrary lends support to the metals theory. Many recent findings still seem to be leaning toward the metals theory.

Wash U published findings on Oct 22 indicating Oligomers as perhaps a target and that is what Prana has been saying all along, and is a target of the PBT2 therapy.

http://news.wustl.edu/news/Pages/24431.aspx

And another recent publication further supporting the metals theory proposed by Prana, and to be proven out hopefully with PBT2
http://www.ncbi.nlm.nih.gov/pubmed/23062696

It seems to be our research is front and center, of course, and why the Big Pharma's do not want to publicize what the medical research findings keep pointing toward.

What a blockbuster announcemnt Phase IIa/b AD & HD trial results could turn out to be